|
Curi Bio and NEXEL Announce Celogics, Joint Venture to Develop Leading iPSC-derived Cell Products
|
Celogics, based in Seattle, will offer high-quality iPSC-derived cell products for drug discovery and safety testing SEATTLE & SEOUL, South Korea--(BUSINESS WIRE)--#biotech--Curi Bio, a global leader in development of human stem cell-based platforms f...
Full "IntellAsia: Resources" article
|
|